{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046513","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.187280+00:00","generated_at":"2026-05-30T03:09:15.272481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Delcath Q3 revenue $11.2M (+44% QoQ); HEPZATO adoption grows; debt-free after warrant exercise","bullets":["Q3 total revenue $11.2M (vs $0.4M prior year); HEPZATO $10.0M, CHEMOSAT $1.2M.","Activated 12 HEPZATO treatment centers in U.S.; additional centers in training pipeline.","Ended Q3 with $14.0M cash; quarterly cash burn $3.6M.","Post-Q3: paid $2.8M final Rosalind note; ~$25M from Tranche B warrant exercise; no debt.","Advancing HEPZATO programs for liver-dominant colorectal and breast cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046513","json":"https://secwatch.observer/filing/0001628280-24-046513.json","markdown":"https://secwatch.observer/filing/0001628280-24-046513.md","text":"https://secwatch.observer/filing/0001628280-24-046513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/0001628280-24-046513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/dcth-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:09:15.272481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}